Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma
Authors:
Open Access
- 1 February 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 91 (3) , 806-812
Abstract
Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively;P < .00001). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels (P = .005), and the median survival time was 21 and 32 months, respectively (P = .002). In a univariate Cox regression analysis, HGF was a significant predictor of mortality (P = .02). In the subgroup of patients with β2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively; P = .0018) than at response (median 0.24 ng/mL, P = .008). We conclude that HGF may be a useful follow-up parameter in myeloma patients. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. HGF was a prognostic factor in patients with high levels of β2-microglobulin.Keywords
This publication has 38 references indexed in Scilit:
- Soluble interleukin‐6 receptor as a prognostic factor in multiple myelomaBritish Journal of Haematology, 1996
- The Effect of Hepatocyte Growth Factor on the Behavior of OsteoclastsBiochemical and Biophysical Research Communications, 1995
- Multiple myeloma: An immunoclinical study of disease and response to treatmentHematological Oncology, 1995
- Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with multiple myeloma at diagnosisBritish Journal of Haematology, 1994
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parametersAnnals of Hematology, 1991
- The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with MyelomaLeukemia & Lymphoma, 1991
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987
- Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma?British Journal of Haematology, 1985
- Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized ratsBiochemical and Biophysical Research Communications, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958